Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., has appointed Dr. Richard Woodman as Chief Clinical Officer of its Oncology Business Group.
Onconova Therapeutics has submitted an application with the National Institute of Allergy and Infectious Disease (NIAID), with the goal of obtaining funding from the National Institutes of Health (NIH) to conduct human studies with rigosertib in COVID-19.